WebDoctor Encyclopedia

Head & neck

Sinonasal Carcinoma

A rare cancer of the nose and sinuses, linked to wood and leather dust exposure, that often mimics sinusitis with one-sided blockage, bleeding or facial swelling.

Medically reviewed Last reviewed November 15, 2026

Sinonasal Carcinoma – A Comprehensive Medical Overview

1. Introduction

Sinonasal carcinoma refers to malignant tumours that arise from the epithelial lining of the nasal cavity and the paranasal sinuses (maxillary, ethmoid, sphenoid and frontal sinuses). Although these cancers are rare – accounting for < 1 % of all head‑and‑neck malignancies – they pose diagnostic and therapeutic challenges because the anatomy is complex, early symptoms are often nonspecific, and treatment must balance oncologic control with preservation of vital functions such as olfaction, respiration, vision and mastication.

Key point: Early recognition of persistent unilateral nasal obstruction, epistaxis or facial pain improves the chance of curative treatment.

2. Epidemiology

Feature Detail
Annual incidence (worldwide) 0.4–0.8 cases per 100 000 persons
Male : Female ratio Approximately 2 : 1 (higher in men)
Peak age 50–70 years; rare < 40 years
Geographic variation Higher rates in regions with prevalent wood‑ dust exposure (e.g., Scandinavia, parts of Asia)
Most common subsite Maximillary sinus (≈ 45 %), followed by ethmoid sinus (≈ 30 %)
Histologic distribution Squamous cell carcinoma (SCC) ~ 55 %; adenocarcinoma ~ 20 %; adenoid cystic carcinoma ~ 10 %; undifferentiated carcinoma ~ 8 %; other (melanoma, sarcoma, lymphoma) ~ 7 %

3. Etiology & Risk Factors

Risk factor Mechanism / Evidence Relative risk (approx.)
Occupational inhalants (wood dust, leather dust, nickel, chromium, formaldehyde) Chronic mucosal irritation → metaplasia → dysplasia 2–5×
Human papillomavirus (HPV) (especially HPV‑16) Viral oncoproteins E6/E7 inactivate p53 & Rb → uncontrolled proliferation 1.5–3× (mostly in non‑keratinizing SCC)
Epstein‑Barr virus (EBV) Detected in a subset of undifferentiated carcinomas, particularly in Asian populations Variable
Smoking Carcinogen exposure; synergistic with occupational dust 1.5–2×
Alcohol consumption Possible co‑factor with smoking modest
Previous radiotherapy (for head‑and‑neck or nasopharyngeal cancer) Radiation‑induced secondary malignancy ↑ after 5–10 years
Genetic syndromes (e.g., Fanconi anemia, Bloom syndrome) DNA repair defects Rare but markedly increased
Chronic sinusitis (especially fungal) Prolonged inflammation may promote malignant change Low‑grade risk

Note: The majority of cases are sporadic; identifiable risk factors are present in ~ 30‑40 % of patients.

4. Pathophysiology

Sinonasal epithelium consists of respiratory (ciliated pseudostratified columnar) and olfactory (specialized neuroepithelial) layers. Carcinogenesis follows a multistep pathway:

  1. Initiation – DNA damage from carcinogens (e.g., polycyclic aromatic hydrocarbons in wood dust) or viral integration (HPV/EBV).
  2. Promotion – Chronic inflammation releases cytokines (IL‑6, TNF‑α) that stimulate proliferative signaling (STAT3, NF‑κB).
  3. Progression – Accumulation of genetic alterations: TP53 mutations (SCC), PIK3CA/AKT pathway activation (adenocarcinoma), NOTCH1 loss (adnexal tumors), and chromosomal instability.
  4. Invasion & Metastasis – Tumor breaches the basement membrane, infiltrates bone (especially the thin walls of the sinuses), spreads via lymphatic routes to regional nodes (submandibular, upper jugular) and hematogenously to lungs, bones or liver.

Because the sinuses are aerated spaces surrounded by thin bony walls, early tumour growth may be submucosal and asymptomatic until it erodes bone or invades adjacent structures (orbit, skull base, cranial nerves).

5. How Does It Look

5.1 Macroscopic (Gross) Appearance

Feature Typical description
Location Most often a unilateral mass filling the maxillary or ethmoid sinus; may expand into the nasal cavity, orbit, or pterygopalatine fossa.
Size at presentation Frequently > 2 cm; lesions < 1 cm are uncommon unless detected incidentally on imaging.
Surface May be ulcerated, friable, or bleed easily on touch. Necrotic centers appear yellow‑white; viable tumor is pink‑tan.
Consistency Ranges from firm (SCC, undifferentiated) to rubbery (adenocarcinoma, adenoid cystic).
Bone involvement Visible erosion or destruction of sinus walls on inspection; occasionally a bony spur protrudes into the nasal cavity.
Extension Invasion of the orbital floor causes proptosis or displacement of the globe; skull base involvement may produce a palpable mass in the nasopharynx.

Clinical tip: On nasal endoscopy, a unilateral polypoidal or necrotic mass that bleeds on gentle suction raises suspicion for carcinoma versus benign polyps.

5.2 Microscopic (Histologic) Appearance

Histologic subtype Key diagnostic features Immunohistochemical markers (typical)
Squamous cell carcinoma (SCC) Keratin pearls, intercellular bridges; varying degrees of differentiation (well‑, moderate‑, poorly‑ differentiated). p40+, p63+, CK5/6+, EGFR+, Ki‑67 variable
Adenocarcinoma Glandular or papillary architecture; mucin production; may show signet‑ring cells. CEA+, CK7+, CK20+, MUC1+, HER2/neu (in some)
Adenoid cystic carcinoma Cribriform, tubular or solid patterns; basaloid cells with hyaline‑like stromal cylinders. CK5/6+, p63+, MYB+, CD117 (c‑Kit) variable
Undifferentiated (sinonasal) carcinoma Sheets of pleomorphic, high‑grade nuclei; minimal keratin or glandular formation; frequent necrosis. p53+, Ki‑67 high (> 70 %), EBV‑EBER+ in endemic cases
Sinonasal undifferentiated carcinoma (SNUC) Similar to undifferentiated carcinoma but with prominent lymphoepithelial component; often EBV‑associated. EBV‑EBER+, CD20+ lymphocytes, CK+, p53+
Mucosal melanoma Nested or sheet‑like melanocytes; pigment may be absent (amelanotic). S100+, SOX10+, Melan‑A+, HMB45− (often)
Sarcoma (e.g., chondrosarcoma, osteosarcoma) Malignant cartilage or bone formation; atypical chondrocytes/osteoblasts. S100+ (chondrogenic), SATB2+ (osteogenic), desmin−

Grading: Most sinonasal carcinomas are graded using the WHO system (G1‑well differentiated → G3‑poorly differentiated). Grade correlates with local invasiveness and metastatic potential.

5.3 Radiologic Appearance

Modality Typical findings
CT (contrast‑enhanced) Soft‑tissue mass attenuating ~ 30‑50 HU; bone destruction or remodeling; cystic necrosis appears as low‑density areas; enhancement after contrast.
MRI (T1/T2, contrast) Tumor is isointense to muscle on T1, hyperintense on T2 (especially adenocarcinoma); post‑contrast enhancement is variable; perineural spread appears as thickening along the Vidian or maxillary nerve.
PET‑CT (FDG) High FDG uptake (SUVmax > 5) in most malignant lesions; useful for detecting occult nodal or distant metastasis.
Ultrasound (transoral/endoscopic) Limited role; can assess cervical nodal involvement.

Imaging tip: When a sinus mass shows bone erosion plus soft‑tissue extension beyond the sinus confines, malignancy should be presumed until proven otherwise.

6. Symptoms

Sinonasal carcinoma often mimics chronic sinusitis or allergic rhinitis, leading to delayed diagnosis. Symptoms are generally unilateral and progressive.

6.1 Early (often subtle) signs

Symptom Description
Nasal obstruction Persistent blockage of one nostril; not relieved by decongestants or steroids.
Epistaxis Intermittent or recurrent bleeding from the same side; may be scant or brisk.
Facial pain / pressure Dull ache over the cheek (maxillary) or between the eyes (ethmoid); worsens with bending forward.
Hyposmia / anosmia Reduced sense of smell on the affected side.
Post‑nasal drip Mucus or blood‑tinged secretion dripping into the throat.

6.2 Advanced signs (indicating local invasion)

Symptom Clinical implication
Proptosis or diplopia Orbital floor or medial wall involvement; may cause vision changes.
Numbness or dysesthesia Infraorbital (V2) or superior alveolar nerve involvement → cheek or upper teeth numbness.
Loose teeth or palate necrosis Invasion of the hard palate or alveolar ridge.
Trismus Tumor extending to the pterygopalatine fossa affecting the medial pterygoid muscle.
Cranial nerve palsies CN VI (abducens) → lateral gaze palsy; CN VII (facial) → facial weakness; CN IX/X → swallowing difficulty.
Neck mass Metastatic lymphadenopathy (most commonly level II‑III).
Systemic symptoms Unexplained weight loss, fatigue, low‑grade fever (rare).

Red‑flag checklist (for clinicians): Unilateral nasal obstruction > 4 weeks, recurrent epistaxis, facial pain unresponsive to medical therapy, visual changes, numbness of cheek/upper teeth, or a neck mass persisting > 2 weeks → urgent ENT referral.

7. Diagnostic Work‑up

  1. Thorough history & physical exam – focus on laterality, duration, risk factors.
  2. Nasal endoscopy (rigid or flexible) – visualise the mass, assess bleeding, obtain targeted biopsies.
  3. Imaging –
  4. CT scan (thin‑cut, bone windows) of the paranasal sinuses and skull base – first‑line for bony detail.
  5. MRI (with and without contrast) – superior for soft‑tissue, perineural, orbital, and intracranial extension assessment.
  6. FDG‑PET/CT – indicated for staging when advanced disease is suspected or to identify occult metastasis.
  7. Biopsy – endoscopic guided punch or forceps biopsy; histology, immunohistochemistry, and molecular profiling (HPV‑PCR, EBV‑EBER, PD‑L1, NTRK fusions if indicated).
  8. Pathologic review – definitive subtype, grade, margin status (if resection performed), lymphovascular invasion, perineural invasion.
  9. Staging – according to the AJCC 8th edition (see Table below).
  10. Multidisciplinary discussion – ENT head‑and‑neck surgeon, medical oncologist, radiation oncologist, radiologist, pathologist, and optionally a prosthodontist or ophthalmologist when orbital/skull base involvement is present.

7.1 AJCC 8th Edition Staging (Sinonasal Cavity)

Stage T (Tumor) N (Nodes) M (Metastasis) Description
0 Tis (carcinoma in situ) N0 M0 Intraepithelial malignancy, no invasion.
I T1 (≤ 2 cm, confined to one sinus/subsite) N0 M0 Small, localized tumor.
II T2 (> 2 cm or involvement of > 1 sinus/subsite, no bone erosion) N0 M0 Larger but still confined.
III T3 (bone erosion or extension into adjacent structures like pterygoid plates, ethmoid labyrinth) or any T with N1 (single ipsilateral node ≤ 3 cm) N0‑N1 M0 Locally advanced or minimal nodal spread.
IVA T4a (moderately advanced: invasion of anterior orbit, skin of cheek, pterygoid fossa, cribriform plate) or any T with N2a‑c (multiple or bilateral nodes ≤ 6 cm) N0‑N2 M0 Advanced local disease with or without nodal involvement.
IVB T4b (very advanced: invasion of brain, cranial nerves IX‑XII, carotid artery) or any T with N3 (node > 6 cm) N0‑N3 M0 Unresectable due to vital structure involvement.
IVC Any T Any N M1 Distant metastasis (lung, bone, liver).

Note: “Tis” refers to carcinoma in situ (rarely diagnosed clinically).

8. Treatment Strategies

Management is multimodal and individualized based on stage, histologic subtype, patient comorbidities, and functional goals. The overarching aims are: (1) achieve local control, (2) prevent regional/distant spread, (3) preserve essential functions (vision, olfaction, speech, mastication), and (4) maintain quality of life.

8.1 Surgery

Procedure Indications Key considerations
Endoscopic sinus surgery (ESS) Early‑stage (T1‑T2) tumors confined to sinus mucosa; selected T3 lesions with minimal bone involvement. Provides excellent visualization; allows margin assessment; preserves facial structures.
Open approaches (midfacial degloving, lateral rhinotomy, Caldwell‑Luc, transfacial, craniofacial) Tumors with extensive bone destruction, orbital or skull base invasion, or need for wide resection. Higher morbidity (facial numbness, epiphora, altered facial contour); may require reconstructive flaps.
Neck dissection (selective or modified radical) Clinically or radiographically positive nodes (N1‑N3) or high‑risk histology (undifferentiated, SNUC) with close margins. Levels II‑IV are most commonly involved; spinal accessory nerve preservation when possible.
Reconstruction Large defects after maxillectomy or orbital exenteration. Microvascular free flaps (e.g., anterolateral thigh, fibula) for bony support; obturator prosthesis for palatal defects.

Surgical margins: Aim for ≥ 5 mm histologic clearance; positive margins often necessitate adjuvant radiotherapy ± chemotherapy.

8.2 Radiotherapy

Modality Typical dose/fractionation Indications
External Beam Radiotherapy (EBRT) – IMRT/VMAT 60–70 Gy in 2‑Gy fractions (standard) or 70 Gy in 2‑Gy fractions with concurrent chemo for high‑risk disease. Post‑operative adjuvant (positive margins, perineural/vascular invasion, advanced T/N); definitive for unresectable or medically inoperable tumors.
Proton Beam Therapy Comparable physical dose, reduced exit dose to orbit, lens, brain. Preferred when tumor proximity to optic structures or brain mandates dose sparing (especially in younger patients).
Brachytherapy (interstitial) Boost dose of 15‑20 Gy to residual disease after EBRT. Occasionally used for recurrent disease confined to sinus mucosa.

Common side effects: mucositis, xerostomia, dysgeusia, skin erythema, transient epistaxis, late effects – cataract, retinal stenosis, osteoradionecrosis of bone, cognitive changes (if temporal lobe irradiated).

8.3 Systemic Therapy

Agent / Regimen Rationale Typical use
Platinum‑based chemotherapy (cisplatin or carboplatin + 5‑FU) DNA crosslinking; synergistic with radiotherapy. Concurrent chemoradiation for locally advanced disease; induction chemotherapy before surgery/radiation in high‑risk cases.
Taxanes (docetaxel, paclitaxel) Microtubule stabilization; active in SCC and adenocarcinoma. Part of TPF (docetaxel + cisplatin + 5‑FU) induction regimen.
EGFR inhibitors (cetuximab) Block epidermal growth factor receptor overexpression (common in SCC). Combined with radiotherapy for patients unsuitable for cisplatin; also in recurrent/metastatic setting.
Immunotherapy (PD‑1/PD‑L1 inhibitors – pembrolizumab, nivolumab) Tumors with high PD‑L1 expression or MSI‑high respond; HPV+ tumors often have a inflamed microenvironment. First‑line or second‑line for recurrent/metastatic disease; being explored in adjuvant trials.
Targeted agents (trastuzumab for HER2+ adenocarcinoma; larotrectinib/entrectinib for NTRK fusions) Actionable molecular alterations identified via next‑generation sequencing. Rare but potentially practice‑changing in selected cases.
Anti‑angiogenic (bevacizumab) VEGF inhibition; modest activity in sinonasal adenocarcinoma. Investigational; used in combination with chemo in metastatic disease.

Molecular testing: For undifferentiated carcinoma, SNUC, or adenocarcinoma, panels assessing HPV, EBV, HER2, NTRK, FGFR, PIK3CA, and PD‑L1 are increasingly recommended to guide therapy.

8.4 Follow‑up & Surveillance

Timeframe Clinical evaluation Imaging
Every 1–3 months (first year) Physical exam, nasal endoscopy, symptom review CT/MRI of sinuses & neck (if high‑risk)
Every 4–6 months (years 2‑3) Same as above Imaging annually or sooner if symptomatic
After 3 years Every 6–12 months Imaging as clinically indicated (usually annual for 5 years)
Beyond 5 years Annual visit Optional imaging based on risk

Late complications (e.g., osteoradionecrosis, chronic xerostomia, secondary malignancies) are monitored throughout life.

9. Prognosis

Prognosis varies markedly by stage, histology, margin status, and treatment modality.

Factor Impact on Survival (5‑year)
Stage I 80‑90 % (endoscopic resection ± radiotherapy)
Stage II 60‑80 %
Stage III 40‑60 % (depends on nodal involvement)
Stage IVA 20‑40 %
Stage IVB/C < 15 % (often palliative)
Histology SCC (moderately differentiated) ~ 55‑70 %; adenocarcinoma ~ 45‑60 %; adenoid cystic carcinoma ~ 50‑70 % (but prone to late local recurrence); undifferentiated carcinoma/SNUC ~ 20‑35 %
Positive margins ↓ 5‑year survival by ~ 20‑30 %
Perineural/vascular invasion ↑ risk of local recurrence & distant metastasis
HPV‑positive SCC Better response to chemoradiation; improved survival vs HPV‑negative (especially in non‑smokers)
EBV‑positive SNUC Variable; some studies show comparable outcomes to HPV+ when treated aggressively.

Overall, 5‑year disease‑specific survival for all sinonasal malignancies approximates 45‑55 %, reflecting the high proportion of patients presenting with advanced disease.

10. Living with Sinonasal Carcinoma

10.1 Rehabilitation

  • Olfactory training – structured sniffing of essential oils may aid smell recovery after surgery or radiation.
  • Prosthetic rehabilitation – obturators for palatal defects, ocular prostheses after orbital exenteration, dental implants for maxillary rehabilitation.
  • Speech & swallowing therapy – crucial if resection involves the hard palate or if chemoradiation causes xerostomia.

10.2 Psychosocial Support

  • Anxiety and depression are common; early referral to psycho‑oncology services improves coping.
  • Support groups (online or hospital‑based) allow sharing of experiences with rare cancers.
  • Vocational rehabilitation may be needed if facial disfigurement or sensory deficits affect employment.

10.3 Lifestyle & Prevention

Measure Rationale
Avoidance of known inhalants (use of respiratory protective equipment in wood‑working, leather tanning, metal industries) Reduces cumulative mucosal damage.
Smoking cessation Lowers synergistic carcinogenic burden.
HPV vaccination (if eligible) May prevent HPV‑related sinonasal SCC (evidence emerging).
Regular ENT check‑ups for high‑risk workers (annual nasendoscopy) Facilitates early detection.
Nasal saline irrigation – not preventive but can alleviate symptoms of chronic sinusitis and reduce crusting.

11. Frequently Asked Questions (FAQs)

Question Brief answer
Is sinonasal carcinoma contagious? No. It is not infectious; however, certain viruses (HPV, EBV) associated with some subtypes can be transmitted, but cancer itself does not spread person‑to‑person.
Can a benign sinus polyp turn into cancer? Rarely. Most polyps are benign; however, long‑standing inflammation can, in very few cases, precede dysplasia. Persistent unilateral polyps should be biopsied.
What is the chance of cure if caught early? For stage I disease treated with endoscopic surgery (± radiotherapy), 5‑year disease‑specific survival exceeds 80 %.
Will I lose my sense of smell permanently? Smell may be impaired after surgery or radiation, but many patients experience partial recovery, especially with olfactory training.
Is proton therapy better than conventional radiation? Protons spare adjacent healthy tissue (e.g., lens, retina) and may reduce late toxicity, but curative rates are comparable when doses are equivalent. Access and cost limit routine use.
Can I still work after treatment? Many patients return to work after rehabilitation; adjustments may be needed depending on the extent of facial or sensory changes.
Are there clinical trials available? Yes – numerous trials investigate immunotherapy combinations, targeted agents (NTRK, FGFR), and de‑intensified protocols for HPV+ disease. Ask your oncology team about eligibility.

12. Resources (Harvard Style)

  1. American Cancer Society. 2023. Sinonasal Cancer. Available at: https://www.cancer.org/cancer/sinus-cancer.html (Accessed: October 2026).
  2. National Comprehensive Cancer Network (NCCN). 2024. Head and Neck Cancers Version 2.2024. Fort Washington, PA: NCCN.
  3. Stanton, M. P., Patel, S. G., & Patel, M. A. 2022. ‘Endoscopic versus open resection for sinonasal malignancies: a systematic review’, Head & Neck, 44(5), pp. 1012‑1025.
  4. Weiss, L. M., et al. 2021. ‘HPV‑related sinonasal squamous cell carcinoma: clinicopathologic features and outcomes’, American Journal of Surgical Pathology, 45(8), pp. 1057‑1066.
  5. Rubin, G. R., et al. 2020. ‘Proton beam therapy for sinonasal malignancies: dosimetric advantages and early clinical outcomes’, International Journal of Radiation Oncology, Biology, Physics, 106(2), pp. 317‑326.
  6. Lee, N. Y., et al. 2019. ‘Neoadjuvant chemotherapy followed by surgery for advanced sinonasal carcinoma: a multi‑institutional analysis’, Annals of Surgical Oncology, 26(9), pp. 2854‑2863.
  7. Brennan, J. A., et al. 2018. ‘Molecular profiling of sinonasal undifferentiated carcinoma reveals actionable NTRK fusions’, Clinical Cancer Research, 24(12), pp. 2859‑2867.
  8. Wang, X., et al. 2017. ‘PD‑L1 expression in sinonasal carcinoma and its correlation with prognosis’, Modern Pathology, 30(10), pp. 1420‑1429.
  9. Shah, J. P., & Gil, Z. 2016. ‘Management of olfactory dysfunction after sinonasal cancer treatment’, Laryngoscope, 126(4), pp. 913‑920.
  10. Takeuchi, A., et al. 2015. ‘Long‑term outcomes of adjuvant radiotherapy after endoscopic sinus surgery for sinonasal malignancy’, European Archives of Oto‑Rhino‑Laryngology, 272(3), pp. 645‑652.

(All URLs accessed October 2026; DOIs omitted for brevity but available upon request.)